Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.

Terazosin, a decades-old drug for enlarged prostate, appears to improve Parkinson's symptoms, tests in animal models and a large patient database show.

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.

The project is built on the AlivaMab Mouse platform that is already widely used by in-house R&D teams at large biopharma companies.

As the White House continues its push for the benefits of "right to try," the first CRO associated with the law has come onto the stage.

Amplyx revealed early data for its lead program in candidemia and licensed a phase 2-ready program for BK virus infection from Novartis.

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.